SUPN Supernus Pharmaceuticals Inc

Price (delayed)

$28.215

Market cap

$1.51B

P/E Ratio

20.3

Dividend/share

N/A

EPS

$1.39

Enterprise value

$1.83B

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for ...

Highlights
Supernus Pharmaceuticals's equity has increased by 10% YoY
Supernus Pharmaceuticals's revenue has increased by 8% YoY and by 3.7% from the previous quarter
The EPS is up by 38% since the previous quarter but it has declined by 34% year-on-year
The company's net income rose by 37% QoQ but it fell by 34% YoY
The debt is up by 12% year-on-year and by 4.7% since the previous quarter

Key stats

What are the main financial stats of SUPN
Market
Shares outstanding
53.41M
Market cap
$1.51B
Enterprise value
$1.83B
Valuations
Price to earnings (P/E)
20.3
Price to book (P/B)
1.81
Price to sales (P/S)
2.5
EV/EBIT
19.03
EV/EBITDA
12.75
EV/Sales
3.05
Earnings
Revenue
$601.35M
EBIT
$96.24M
EBITDA
$143.6M
Free cash flow
$93.84M
Per share
EPS
$1.39
Free cash flow per share
$1.76
Book value per share
$15.58
Revenue per share
$11.28
TBVPS
$14.25
Balance sheet
Total assets
$1.64B
Total liabilities
$811.07M
Debt
$440.27M
Equity
$828.45M
Working capital
$283.96M
Liquidity
Debt to equity
0.53
Current ratio
2
Quick ratio
1.61
Net debt/EBITDA
2.26
Margins
EBITDA margin
23.9%
Gross margin
87%
Net margin
12.2%
Operating margin
11%
Efficiency
Return on assets
4.5%
Return on equity
9.1%
Return on invested capital
10.6%
Return on capital employed
7.1%
Return on sales
16%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SUPN stock price

How has the Supernus Pharmaceuticals stock price performed over time
Intraday
-0.58%
1 week
1.64%
1 month
-0.65%
1 year
-10.8%
YTD
-3.24%
QTD
-12.7%

Financial performance

How have Supernus Pharmaceuticals's revenue and profit performed over time
Revenue
$601.35M
Gross profit
$523.31M
Operating income
$66.03M
Net income
$73.35M
Gross margin
87%
Net margin
12.2%
The company's operating margin has shrunk by 61% YoY and by 26% QoQ
SUPN's operating income has plunged by 58% YoY and by 23% from the previous quarter
The net margin is down by 39% year-on-year but it is up by 33% since the previous quarter
The company's net income rose by 37% QoQ but it fell by 34% YoY

Growth

What is Supernus Pharmaceuticals's growth rate over time

Valuation

What is Supernus Pharmaceuticals stock price valuation
P/E
20.3
P/B
1.81
P/S
2.5
EV/EBIT
19.03
EV/EBITDA
12.75
EV/Sales
3.05
The EPS is up by 38% since the previous quarter but it has declined by 34% year-on-year
The stock's price to earnings (P/E) is 4.6% less than its last 4 quarters average of 21.4 but 3.1% more than its 5-year quarterly average of 19.8
SUPN's price to book (P/B) is 53% less than its 5-year quarterly average of 3.9 and 9% less than its last 4 quarters average of 2.0
Supernus Pharmaceuticals's equity has increased by 10% YoY
The P/S is 43% below the 5-year quarterly average of 4.4 and 7% below the last 4 quarters average of 2.7
Supernus Pharmaceuticals's revenue has increased by 8% YoY and by 3.7% from the previous quarter

Efficiency

How efficient is Supernus Pharmaceuticals business performance
The return on sales has declined by 49% year-on-year and by 4.2% since the previous quarter
SUPN's return on invested capital is down by 43% year-on-year but it is up by 3.9% since the previous quarter
The company's return on equity fell by 41% YoY but it rose by 36% QoQ
The return on assets has declined by 39% year-on-year but it has grown by 32% since the previous quarter

Dividends

What is SUPN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SUPN.

Financial health

How did Supernus Pharmaceuticals financials performed over time
Supernus Pharmaceuticals's total assets is 102% higher than its total liabilities
The quick ratio has contracted by 25% YoY but it has grown by 3.9% from the previous quarter
SUPN's current ratio is down by 18% year-on-year but it is up by 4.7% since the previous quarter
The debt is 47% smaller than the equity
The debt is up by 12% year-on-year and by 4.7% since the previous quarter
Supernus Pharmaceuticals's equity has increased by 10% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.